Dual effect of oxidative stress on leukemia cancer induction and treatment

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Udensi, Udensi K ^a   Tchounwou, Paul B ^a  

^a Jackson State University   (United States)

Author keywords

Antioxidants; Apoptosis; Leukemia; Oxidative stress; Reactive oxygen species; Treatment

Indexed keywords

ANTIOXIDANT; OXYGEN RADICAL; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER GROWTH; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; DNA DAMAGE; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA; LEUKEMOGENESIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; ANIMAL; CELL TRANSFORMATION; DRUG EFFECTS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LEUKEMIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84924099764     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-014-0106-5     Document Type: Review

References (170)

1. Finkel T: Oxidant signals and oxidative stress. Curr Opin Cell Biol 2003, 15:247-254.
2. Kumar S, Yedjou CG, Tchounwou PB: Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells. J Exp Clin Cancer Res 2014, 33:42.
3. Ristow M, Zarse K: How increased oxidative stress promotes longevity and metabolic health: The concept of mitochondrial hormesis (mitohormesis). Exp Gerontol 2010, 45:410-418.
4. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
5. Weinberg F, Chandel NS: Reactive oxygen species-dependent signaling regulates cancer. Cell Mol Life Sci 2009, 66:3663-3673.
6. Lau AT, Wang Y, Chiu JF: Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J Cell Biochem 2008, 104:657-667.
7. Renschler MF: The emerging role of reactive oxygen species in cancer therapy. Eur J Cancer 2004, 40:1934-1940.
8. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK: Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008, 68:1777-1785.
9. Fried L, Arbiser JL: The reactive oxygen-driven tumor: relevance to melanoma. Pigment Cell Melanoma Res 2008, 21:117-122.
10. Battisti V, Maders LD, Bagatini MD, Santos KF, Spanevello RM, Maldonado PA, Brulé AO, Araújo Mdo C, Schetinger MR, Morsch VM: Measurement of oxidative stress and antioxidant status in acute lymphoblastic leukemia patients. Clin Biochem 2008, 41:511-518.
11. Farquhar MJ, Bowen DT: Oxidative stress and the myelodysplastic syndromes. Int J Hematol 2003, 77:342-350.
12. Sallmyr A, Fan J, Rassool FV: Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett 2008, 270:1-9.
13. Wilson JN, Pierce JD, Clancy RL: Reactive oxygen species in acute respiratory distress syndrome. Heart Lung 2001, 30:370-375.
14. Dugan LL, Quick KL: Reactive oxygen species and aging: evolving questions. Sci Aging Knowledge Environ 2005, 2005:e20.
15. Hensley K, Butterfield DA, Hall N, Cole P, Subramaniam R, Mark R, Mattson MP, Markesbery WR, Harris ME, Aksenov M, Aksenova M, Wu JF, Carney JM: Reactive oxygen species as causal agents in the neurotoxicity of the Alzheimer's disease-associated amyloid beta peptide. Ann N Y Acad Sci 1996, 786:120-134.
16. Halliwell B: Free radicals, reactive oxygen species and human disease: a critical evaluation with special reference to atherosclerosis. Br J Exp Pathol 1989, 70:737-757.
17. Touyz RM: Reactive oxygen species and angiotensin II signaling in vascular cells - implications in cardiovascular disease. Braz J Med Biol Res 2004, 37:1263-1273.
18. Muhammad S, Bierhaus A, Schwaninger M: Reactive oxygen species in diabetes-induced vascular damage, stroke, and Alzheimer's disease. J Alzheimers Dis 2009, 16:775-785.
19. Di VF: New pathways for reactive oxygen species generation in inflammation and potential novel pharmacological targets. Curr Pharm Des 2004, 10:1647-1652.
20. Moulton PJ: Inflammatory joint disease: the role of cytokines, cyclooxygenases and reactive oxygen species. Br J Biomed Sci 1996, 53:317-324.
21. Bolanos JP, Moro MA, Lizasoain I, Almeida A: Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: Therapeutic implications. Adv Drug Deliv Rev 2009, 61:1299-1315.
22. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752-1761.
23. Tieu K, Ischiropoulos H, Przedborski S: Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB Life 2003, 55:329-335.
24. Kinnula VL, Fattman CL, Tan RJ, Oury TD: Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005, 172:417-422.
25. Gelderman KA, Hultqvist M, Olsson LM, Bauer K, Pizzolla A, Olofsson P, Holmdahl R: Rheumatoid arthritis: the role of reactive oxygen species in disease development and therapeutic strategies. Antioxid Redox Signal 2007, 9:1541-1567.
26. Jeremy JY, Shukla N, Muzaffar S, Handley A, Angelini GD: Reactive oxygen species, vascular disease and cardiovascular surgery. Curr Vasc Pharmacol 2004, 2:229-236.
27. Maraldi T, Prata C, Vieceli Dalla Sega F, Caliceti C, Zambonin L, Fiorentini D, Hakim G: NAD (P) H oxidase isoform Nox2 plays a prosurvival role in human leukaemia cells. Free Radic Res 2009, 43:1111-1121.
28. Naughton R, Quiney C, Turner SD, Cotter TG: Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia 2009, 23:1432-1440.
29. Arnold RS, He J, Remo A, Ritsick D, Yin-Goen Q, Lambeth JD, Datta MW, Young AN, Petros JA: Nox1 expression determines cellular reactive oxygen and modulates c-fos-induced growth factor, interleukin-8, and Cav-1. Am J Pathol 2007, 171:2021-2032.
30. Wu WS, Wu JR, Hu CT: Signal cross talks for sustained MAPK activation and cell migration: the potential role of reactive oxygen species. Cancer Metastasis Rev 2008, 27:303-314.
31. Trachootham D, Alexandre J, Huang P: Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009, 8:579-591.
32. Gorrini C, Harris IS, Mak TW: Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 2013, 12:931-947.
33. Jones DP: Radical-free biology of oxidative stress. Am J Physiol Cell Physiol 2008, 295:C849-C868.
34. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J: Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 2004, 266:37-56.
35. Arrigo AP: Gene expression and the thiol redox state. Free Radic Biol Med 1999, 27:936-944.
36. Finkel T, Holbrook NJ: Oxidants, oxidative stress and the biology of ageing. Nature 2000, 408:239-247.
37. Nathan C: Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. J Clin Invest 2003, 111:769-778.
38. Kroncke KD: Nitrosative stress and transcription. Biol Chem 2003, 384:1365-1377.
39. Halliwell B, Gutteridge J: Free radicals in biology and medicine. 3rd edition. Oxford: Clarendon; 1999.
40. Niklowitz P, Wiesel T, Andler W, Menke T: Coenzyme Q10 concentration in the plasma of children suffering from acute lymphoblastic leukaemia before and during induction treatment. Biofactors 2007, 29:83-89.
41. Liu CX, Zhou HC, Yin QQ, Wu YL, Chen GQ: Targeting peroxiredoxins against leukemia. Exp Cell Res 2013, 319:170-176.
42. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006, 160:1-40.
43. Devi GS, Prasad MH, Saraswathi I, Raghu D, Rao DN, Reddy PP: Free radicals antioxidant enzymes and lipid peroxidation in different types of leukemias. Clin Chim Acta 2000, 293:53-62.
44. Poli G, Leonarduzzi G, Biasi F, Chiarpotto E: Oxidative stress and cell signalling. Curr Med Chem 2004, 11:1163-1182.
45. Inoue M, Sato EF, Nishikawa M, Park AM, Kira Y, Imada I, Utsumi K: Mitochondrial generation of reactive oxygen species and its role in aerobic life. Curr Med Chem 2003, 10:2495-2505.
46. Conner EM, Grisham MB: Inflammation, free radicals, and antioxidants. Nutrition 1996, 12:274-277.
47. Ames BN, Shigenaga MK, Hagen TM: Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A 1993, 90:7915-7922.
48. Cadenas E: Biochemistry of oxygen toxicity. Annu Rev Biochem 1989, 58:79-110.
49. Loschen G, Flohe L, Chance B: Respiratory chain linked H (2) O (2) production in pigeon heart mitochondria. FEBS Lett 1971, 18:261-264.
50. Li C, Jackson RM: Reactive species mechanisms of cellular hypoxiareoxygenation injury. Am J Physiol Cell Physiol 2002, 282:C227-C241.
51. Gupta M, Dobashi K, Greene EL, Orak JK, Singh I: Studies on hepatic injury and antioxidant enzyme activities in rat subcellular organelles following in vivo ischemia and reperfusion. Mol Cell Biochem 1997, 176:337-347.
52. Fransen M, Nordgren M, Wang B, Apanasets O: Role of peroxisomes in ROS/RNS-metabolism: implications for human disease. Biochim Biophys Acta 1822, 2012:1363-1373.
53. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB: Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010, 49:1603-1616.
54. Görlach A, Berchner-Pfannschmidt U, Wotzlaw C, Cool RH, Fandrey J, Acker H, Jungermann K, Kietzmann T: Reactive oxygen species modulate HIF-1 mediated PAI-1 expression: involvement of the GTPase Rac1. Thromb Haemost 2003, 89:926-935.
55. Velasco-Hernandez T, Hyrenius-Wittsten A, Rehn M, Bryder D, Cammenga J: HIF-1alpha can act as a tumor suppressor gene in murine Acute Myeloid Leukemia. Blood 2014, 124(24):3597-3607.
56. Surh YJ, Kundu JK, Na HK, Lee JS: Redox-sensitive transcription factors as prime targets for chemoprevention with anti-inflammatory and antioxidative phytochemicals. J Nutr 2005, 135:2993S-3001S.
57. Eferl R, Wagner EF: AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003, 3:859-868.
58. Verde P, Casalino L, Talotta F, Yaniv M, Weitzman JB: Deciphering AP-1 function in tumorigenesis: fra-ternizing on target promoters. Cell Cycle 2007, 6:2633-2639.
59. Browatzki M, Larsen D, Pfeiffer CA, Gehrke SG, Schmidt J, Kranzhofer A, Katus HA, Kranzhofer R: Angiotensin II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear factor-kappaB and activator protein 1 in a redox-sensitive manner. J Vasc Res 2005, 42:415-423.
60. Saito T, Itoh H, Yamashita J, Doi K, Chun TH, Tanaka T, Inoue M, Masatsugu K, Fukunaga Y, Sawada N, Sakaguchi S, Arai H, Tojo K, Tajima N, Hosoya T, Nakao K: Angiotensin II suppresses growth arrest specific homeobox (Gax) expression via redox-sensitive mitogen-activated protein kinase (MAPK). Regul Pept 2005, 127:159-167.
61. Gorski DH, LePage DF, Patel CV, Copeland NG, Jenkins NA, Walsh K: Molecular cloning of a diverged homeobox gene that is rapidly down-regulated during the G0/G1 transition in vascular smooth muscle cells. Mol Cell Biol 1993, 13:3722-3733.
62. Gausdal G, Wergeland A, Skavland J, Nguyen E, Pendino F, Rouhee N, McCormack E, Herfindal L, Kleppe R, Havemann U, Schwede F, Bruserud O, Gjertsen BT, Lanotte M, Ségal-Bendirdjian E, Døskeland SO: Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death Dis 2013, 4:e516.
63. Faber K, Bullinger L, Ragu C, Garding A, Mertens D, Miller C, Martin D, Walcher D, Döhner K, Döhner H, Claus R, Plass C, Sykes SM, Lane SW, Scholl C, Fröhling S: CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARgamma signaling. J Clin Invest 2013, 123:299-314.
64. Liu Y, Elf SE, Asai T, Miyata Y, Liu Y, Sashida G, Huang G, Di Giandomenico S, Koff A, Nimer SD: The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior. Cell Cycle 2009, 8:3120-3124.
65. Breccia M, Alimena G: Efficacy and safety of deferasirox in myelodysplastic syndromes. Ann Hematol 2013, 92:863-870.
66. Uckun FM, Qazi S, Ma H, Tuel-Ahlgren L, Ozer Z: STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proc Natl Acad Sci U S A 2010, 107:2902-2907.
67. Cadenas E, Davies KJ: Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 2000, 29:222-230.
68. Rizzo AM, Berselli P, Zava S, Montorfano G, Negroni M, Corsetto P, Berra B: Endogenous antioxidants and radical scavengers. Adv Exp Med Biol 2010, 698:52-67.
69. Burton GW, Ingold KU: Vitamin E as an in vitro and in vivo antioxidant. Ann N Y Acad Sci 1989, 570:7-22.
70. Cai Y, Sun M, Corke H: Antioxidant activity of betalains from plants of the amaranthaceae. J Agric Food Chem 2003, 51:2288-2294.
71. Zheng W, Wang SY: Antioxidant activity and phenolic compounds in selected herbs. J Agric Food Chem 2001, 49:5165-5170.
72. Oberley LW, Buettner GR: Role of superoxide dismutase in cancer: a review. Cancer Res 1979, 39:1141-1149.
73. Manoharan S, Kolanjiappan K, Kayalvizhi M: Enhanced lipid peroxidation and impaired enzymic antioxidant activities in the erythrocytes of patients with cervical carcinoma. Cell Mol Biol Lett 2004, 9:699-707.
74. Oktyabrsky ON, Smirnova GV: Redox regulation of cellular functions. Biochemistry (Mosc) 2007, 72:132-145.
75. Catalani S, Carbonaro V, Palma F, Arshakyan M, Galati R, Nuvoli B, Battistelli S, Canestrari F, Benedetti S: Metabolism modifications and apoptosis induction after Cellfood administration to leukemia cell lines. J Exp Clin Cancer Res 2013, 32:63.
76. Chang C, Zhu YQ, Mei JJ, Liu SQ, Luo J: Involvement of mitochondrial pathway in NCTD-induced cytotoxicity in human hepG2 cells. J Exp Clin Cancer Res 2010, 29:145.
77. Yamamoto JF, Goodman MT: Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008, 19:379-390.
78. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
79. Chung YJ, Robert C, Gough SM, Rassool FV, Aplan PD: Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome. Leuk Res 2014, 38:95-102.
80. CDC: Cancer Among Children, Cancer Prevention and Control. http://www.cdc.gov/cancer/dcpc/data/children. htm. Retrieved 6/5/2014. 2014.
81. NCI: Surveillance, Epidemiology, and End Results (SEER) Program, Stat Fact Sheets: Leukemia. http://seer.cancer.gov/statfacts/html/leuks.html. Retrieved 6/5/2014. 2014. National Cancer Institute.
82. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
83. Mathers CD, Shibuya K, Boschi-Pinto C, Lopez AD, Murray CJ: Global and regional estimates of cancer mortality and incidence by site: I. Application of regional cancer survival model to estimate cancer mortality distribution by site. BMC Cancer 2002, 2:36.
84. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
85. Vyas P, Jacobsen SE: Clever leukemic stem cells branch out. Cell Stem Cell 2011, 8:242-244.
86. Kennedy JA, Barabe F: Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia. Leukemia 2008, 22:2029-2040.
87. NCI: Leukemia, National Cancer Institute (NCI). http://www.cancer.gov/cancertopics/wyntk/leukemia/page1. Retrieved 6/5/2014. 2014.
88. Notta F, Mullighan CG, Wang JC, Poeppl A, Doulatov S, Phillips LA, Ma J, Minden MD, Downing JR, Dick JE: Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011, 469:362-367.
89. CTCA: Leukemia types. http://www.cancercenter.com/leukemia/types/tab/chronic-myeloid-leukemia/, Cancer Treatment Centers of America (CTCA). Retrieved 8/04/2014.
90. Orazi A, Germing U: The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 2008, 22:1308-1319.
91. Niemeyer CM, Kratz CP, Hasle H: Pediatric myelodysplastic syndromes. Curr Treat Options Oncol 2005, 6:209-214.
92. Germing U, Gattermann N, Strupp C, Aivado M, Aul C: Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000, 24:983-992.
93. Bhatia S, Neglia JP: Epidemiology of childhood acute myelogenous leukemia. J Pediatr Hematol Oncol 1995, 17:94-100.
94. Austin C: Does oxidative damage contribute to the generation of leukemia? Leuk Res 2009, 33:1297.
95. Zhou F, Zhang W, Wei Y, Zhou D, Su Z, Meng X, Hui L, Tian W: The changes of oxidative stress and human 8-hydroxyguanine glycosylase1 gene expression in depressive patients with acute leukemia. Leuk Res 2007, 31:387-393.
96. Troy JD, Atallah E, Geyer JT, Saber W: Myelodysplastic syndromes in the United States: an update for clinicians. Ann Med 2014, 46(5):283-289.
97. Shipp MA, Vijayaraghavan J, Schmidt EV, Masteller EL, D'Adamio L, Hersh LB, Reinherz EL: Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): direct evidence by cDNA transfection analysis. Proc Natl Acad Sci U S A 1989, 86:297-301.
98. Zhuo W, Zhang L, Wang Y, Zhu B, Chen Z: CYP1A1 MspI polymorphism and acute myeloid leukemia risk: meta-analyses based on 5018 subjects. J Exp Clin Cancer Res 2012, 31:62.
99. Linker CA: Autologous stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant 2003, 31:731-738.
100. Marcus RE, Matutes E, Drysdale H, Catovsky D: Phenotypic conversion of TdT+ adult AML to CALLA+ ALL. Scand J Haematol 1985, 35:343-347.
101. Smits EL, Berneman ZN, Van Tendeloo VF: Immunotherapy of acute myeloid leukemia: current approaches. Oncologist 2009, 14:240-252.
102. Marbello L, Ricci F, Nosari AM, Turrini M, Nador G, Nichelatti M, Tedeschi A, Vismara E, Morra E: Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. Leuk Res 2008, 32:1221-1227.
103. Faderl S, Kantarjian HM, Talpaz M: Chronic myelogenous leukemia: update on biology and treatment. Oncology (Williston Park) 1999, 13:169-180.
104. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M, Heisterkamp N, Stephenson JR, Groffen J: Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983, 306:277-280.
105. Rowley JD: Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
106. Long B, Zhu H, Zhu C, Liu T, Meng W: Activation of the Hedgehog pathway in chronic myelogeneous leukemia patients. J Exp Clin Cancer Res 2011, 30:8.
107. Padron E, Komrokji R, List AF: The clinical management of chronic myelomonocytic leukemia. Clin Adv Hematol Oncol 2014, 12:172-178.
108. Emanuel PD: Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia 2008, 22:1335-1342.
109. Pardanani A, Tefferi A: Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 2004, 104:1931-1939.
110. Tallman MS, Altman JK: How I treat acute promyelocytic leukemia. Blood 2009, 114:5126-5135.
111. Paulson K, Serebrin A, Lambert P, Bergeron J, Everett J, Kew A, Jones D, Mahmud S, Meloche C, Sabloff M, Sharif I, Storring J, Turner D, Seftel MD: Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol 2014, 166(5):660-666.
112. Rowley JD, Golomb HM, Dougherty C:15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977, 1:549-550.
113. Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, Pelicci PG: The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993, 74:423-431.
114. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, Pandolfi PP: PML is essential for multiple apoptotic pathways. Nat Genet 1998, 20:266-272.
115. Quignon F, De BF, Koken M, Feunteun J, Ameisen JC, de Thé H: PML induces a novel caspase-independent death process. Nat Genet 1998, 20:259-265.
116. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic Leukemia: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
117. Jitschin R, Hofmann AD, Bruns H, Giessl A, Bricks J, Berger J, Saul D, Eckart MJ, Mackensen A, Mougiakakos D: Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood 2014, 123:2663-2672.
118. Lo CF, Nervi C, Avvisati G, Mandelli F: Acute promyelocytic leukemia: a curable disease. Leukemia 1998, 12:1866-1880.
119. Chlapek P, Redova M, Zitterbart K, Hermanova M, Sterba J, Veselska R: Enhancement of ATRA-induced differentiation of neuroblastoma cells with LOX/COX inhibitors: an expression profiling study. J Exp Clin Cancer Res 2010, 29:45.
120. Faderl S, Jeha S, Kantarjian HM: The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003, 98:1337-1354.
121. Espérou H, Boiron JM, Cayuela JM, Blanchet O, Kuentz M, Jouet JP, Milpied N, Cahn JY, Faucher C, Bourhis JH, Michallet M, Tanguy ML, Vernant JP, Gabert J, Bordigoni P, Ifrah N, Baruchel A, Dombret H, French Bone Marrow Transplantation: A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant 2003, 31:909-918.
122. Hu Y, Gu X, Li R, Luo Q, Xu Y: Glycogen synthase kinase-3beta inhibition induces nuclear factor-kappaB-mediated apoptosis in pediatric acute lymphocyte leukemia cells. J Exp Clin Cancer Res 2010, 29:154.
123. Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Spinelli O, Tosi M, Oldani E, Intermesoli T, Rambaldi A: Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010, 28:3644-3652.
124. Chavez JC, Sahakian E, Pinilla-Ibarz J: Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid 2013, 8:37-45.
125. Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
126. Gribben JG: How I treat CLL up front. Blood 2010, 115:187-197.
127. Hamblin AD, Hamblin TJ: The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull 2008, 87:49-62.
128. Hjalmar V, Kimby E, Matutes E, Sundstrom C, Wallvik J, Hast R: Atypical lymphocytes in B-cell chronic lymphocytic leukemia and trisomy 12 studied by conventional staining combined with fluorescence in situ hybridization. Leuk Lymphoma 2000, 37:571-576.
129. Parmar S, Patel K, Pinilla-Ibarz J: Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2014, 39:483-519.
130. Zhang X, Machii T, Matsumura I, Ezoe S, Kawasaki A, Tanaka H, Ueda S, Sugahara H, Shibayama H, Mizuki M, Kanakura Y: Constitutively activated Rho guanosine triphosphatases regulate the growth and morphology of hairy cell leukemia cells. Int J Hematol 2003, 77:263-273.
131. Wrede JE, Sundram U, Kohler S, Cherry AM, Arber DA, George TI: Fluorescence in situ hybridization investigation of cutaneous lesions in acute promyelocytic leukemia. Mod Pathol 2005, 18:1569-1576.
132. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Miyazawa T, Ishibashi K, Horie T, Imai K, Todoroki T, Kimura S, Koike K: Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001, 61:4365-4370.
133. Wiseman H, Halliwell B: Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 1996, 313(Pt 1):17-29.
134. Cerutti PA, Trump BF: Inflammation and oxidative stress in carcinogenesis. Cancer Cells 1991, 3:1-7.
135. Dreher D, Junod AF: Role of oxygen free radicals in cancer development. Eur J Cancer 1996, 32 A:30-38.
136. Cerutti PA: Oxy-radicals and cancer. Lancet 1994, 344:862-863.
137. Adler V, Yin Z, Tew KD, Ronai Z: Role of redox potential and reactive oxygen species in stress signaling. Oncogene 1999, 18:6104-6111.
138. Oltra AM, Carbonell F, Tormos C, Iradi A, Saez GT: Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic leukemia. Free Radic Biol Med 2001, 30:1286-1292.
139. Nishiura T, Suzuki K, Kawaguchi T, Nakao H, Kawamura N, Taniguchi M, Kanayama Y, Yonezawa T, Iizuka S, Taniguchi N: Elevated serum manganese superoxide dismutase in acute leukemias. Cancer Lett 1992, 62:211-215.
140. Silber R, Farber CM, Papadopoulos E, Nevrla D, Liebes L, Bruck M, Brown R, Canellakis ZN: Glutathione depletion in chronic lymphocytic leukemia B lymphocytes. Blood 1992, 80:2038-2043.
141. Flora SJ: Structural, chemical and biological aspects of antioxidants for strategies against metal and metalloid exposure. Oxid Med Cell Longev 2009, 2:191-206.
142. Estey E, Dohner H: Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
143. Moore N, Lyle S: Quiescent, slow-cycling stem cell populations in cancer: A review of the evidence and discussion of significance. J Oncol 2011, 2011: Article ID:396076.
144. Augustin W, Wiswedel I, Noack H, Reinheckel T, Reichelt O: Role of endogenous and exogenous antioxidants in the defence against functional damage and lipid peroxidation in rat liver mitochondria. Mol Cell Biochem 1997, 174:199-205.
145. Guachalla LM, Rudolph KL: ROS induced DNA damage and checkpoint responses: influences on aging? Cell Cycle 2010, 9:4058-4060.
146. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C: Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 2008, 123:1227-1239.
147. Hole PS, Darley RL, Tonks A: Do reactive oxygen species play a role in myeloid leukemias? Blood 2011, 117:5816-5826.
148. Schuurman AG, Goldbohm RA, Brants HA, van den Brandt PA: A prospective cohort study on intake of retinol, vitamins C and E, and carotenoids and prostate cancer risk (Netherlands). Cancer Causes Control 2002, 13:573-582.
149. Fleischauer AT, Olson SH, Mignone L, Simonsen N, Caputo TA, Harlap S: Dietary antioxidants, supplements, and risk of epithelial ovarian cancer. Nutr Cancer 2001, 40:92-98.
150. Rodrigues MS, Reddy MM, Sattler M: Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications. Antioxid Redox Signal 2008, 10:1813-1848.
151. Yu C, Rahmani M, Dent P, Grant S: The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp Cell Res 2004, 295:555-566.
152. Laurent G, Jaffrezou JP: Signaling pathways activated by daunorubicin. Blood 2001, 98:913-924.
153. Yedjou CG, Tchounwou PB: In vitro assessment of oxidative stress and apoptotic mechanisms of garlic extract in the treatment of acute promyelocytic leukemia. J Cancer Sci Ther 2012, 2012:6.
154. Townsend DM, Findlay VL, Tew KD: Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets. Methods Enzymol 2005, 401:287-307.
155. Miyazaki T, Kirino Y, Takeno M, Samukawa S, Hama M, Tanaka M, Yamaji S, Ueda A, Tomita N, Fujita H, Ishigatsubo Y: Expression of heme oxygenase-1 in human leukemic cells and its regulation by transcriptional repressor Bach1. Cancer Sci 2010, 101:1409-1416.
156. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, Keating MJ, Huang P: Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 2008, 112:1912-1922.
157. Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ, Arlinghaus RB, Huang P: Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 2008, 22:1191-1199.
158. Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, Kaufmann SH: Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood 2006, 107:2501-2506.
159. Lu J, Chew EH, Holmgren A: Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A 2007, 104:12288-12293.
160. Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W, Keating MJ, Huang P: Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 2003, 278:37832-37839.
161. Wang J, Li L, Cang H, Shi G, Yi J: NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells. Leuk Res 2008, 32:429-436.
162. Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le BM, Duffort S, Peres L, Berthier C, Soilihi H, Raught B, de Thé H: PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 2010, 18:88-98.
163. Doudican NA, Bowling B, Orlow SJ: Enhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism. Leuk Res 2010, 34:229-234.
164. Yedjou C, Tchounwou P, Jenkins J, McMurray R: Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. J Hematol Oncol 2010, 3:28.
165. Rogers CS, Yedjou CG, Sutton DJ, Tchounwou PB: Vitamin D3 potentiates the antitumorigenic effects of arsenic trioxide in human leukemia (HL-60) cells. Exp Hematol Oncol 2014, 3:9.
166. Yedjou C, Thuisseu L, Tchounwou C, Gomes M, Howard C, Tchounwou P: Ascorbic acid potentiation of arsenic trioxide anticancer activity against acute promyelocytic leukemia. Arch Drug Inf 2009, 2:59-65.
167. Yedjou CG, Rogers C, Brown E, Tchounwou PB: Differential effect of ascorbic acid and n-acetyl-L-cysteine on arsenic trioxide-mediated oxidative stress in human leukemia (HL-60) cells. J Biochem Mol Toxicol 2008, 22:85-92.
168. Mochizuki T, Furuta S, Mitsushita J, Shang WH, Ito M, Yokoo Y, Yamaura M, Ishizone S, Nakayama J, Konagai A, Hirose K, Kiyosawa K, Kamata T: Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene 2006, 25:3699-3707.
169. Conklin KA: Cancer chemotherapy and antioxidants. J Nutr 2004, 134:3201S-3204S.
170. Meyskens FL Jr, Kopecky KJ, Appelbaum FR, Balcerzak SP, Samlowski W, Hynes H: Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. Leuk Res 1995, 19:605-612.